Kevin C Tang bought $12M of AUPH
Chief Executive Officer at Aurinia Pharmaceuticals Inc.. 814,606 shares at an average of $15.29, traded May 29, 2026, filed Jun 2, 2026.
Score components
- +25RoleCEO
- +25Trade size$12.5M at market
- +3Relative to holdingsHoldings up 7%
- 0Price contextNear the top of the 52-week range
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001178579-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 29, 2026 | POpen-market purchase Common Sharesindirect: By LP | +2,299 | $15.35 | $35k | 12,231,799 | Jun 2, 2026 |
| May 29, 2026 | POpen-market purchase Common Sharesindirect: By LP | +262,682 | $15.31 | $4.0M | 12,494,481 | Jun 2, 2026 |
| Jun 1, 2026 | POpen-market purchase Common Sharesindirect: By LP | +343,521 | $15.28 | $5.2M | 12,838,002 | Jun 2, 2026 |
| Jun 1, 2026 | POpen-market purchase Common Sharesindirect: By LP | +99 | $15.34 | $1,519 | 12,838,101 | Jun 2, 2026 |
| Jun 2, 2026 | POpen-market purchase Common Sharesindirect: By LP | +206,005 | $15.28 | $3.1M | 13,044,106 | Jun 2, 2026 |
| Jun 2, 2026 | JOther Short Put Options (potential obligation to buy)derivativeindirect: By LP | +10,000 | $1.65 | $17k | 10,000 | Jun 2, 2026 |
Related signals
Other insiders at Aurinia Pharmaceuticals Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 27Weak | AUPHsell Aurinia Pharmaceuticals Inc. | Stephen P. Robertson Chief Legal Officer | $190k 11,939 shares | -2% | |
| 30Weak | AUPHsell Aurinia Pharmaceuticals Inc. | Stephen P. Robertson Chief Legal Officer | $356k 20,975 shares | -3% | |
| 43Moderate | AUPHbuy Aurinia Pharmaceuticals Inc. | Kevin C Tang Chief Executive Officer | $13M 900,000 shares | +8% | |
| 43Moderate | AUPHbuy Aurinia Pharmaceuticals Inc. | Kevin C Tang Chief Executive Officer | $14M 1,300,000 shares | +13% | |
| 32Weak | AUPHsell Aurinia Pharmaceuticals Inc. | Greg Keenan Chief Medical Officer | $210k 20,000 shares | -13% | |
| 38Weak | Aurinia Pharmaceuticals Inc. | Greg Keenan Chief Medical Officer | $68k 8,305 shares | -5% | |
| 48Moderate | AUPHbuy Aurinia Pharmaceuticals Inc. | Kevin C Tang Chief Executive Officer | $13M 1,600,000 shares | +19% | |
| 65Notable | Aurinia Pharmaceuticals Inc. | Matthew Maxwell Donley Chief Operating Officer | $994k 124,893 shares | -16% | |
| 60Notable | Aurinia Pharmaceuticals Inc. | Stephen P. Robertson EVP, General Counsel | $975k 122,479 shares | -19% | |
| 66Notable | Aurinia Pharmaceuticals Inc. | Joseph M Miller Chief Financial Officer | $940k 118,013 shares | -17% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.